Amedisys — Q4 2017 Earnings Presentation
27 slides from Amedisys's earnings presentation, Feb 27, 2018
Slide 1: Fourth Quarter 2017 Earnings Call Supplemental Slides
Amedisys Fourth Quarter 2017 Earnings Call Supplemental Slides February 28th, 2018 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau
Slide 3: Investment Rationale
Investment Rationale Favorable patient demographics, strong revenue and EBITDA growth in the face of rate cuts, a pristine balance sheet and an advantageous capital position make Amedisys an attractive investment Strategic Positioning Financial Performance Impact on System Leader in Quality Demograp
Slide 4: Our Key Areas of Focus
Our Key Areas of Focus Strategic areas of focus for 2018 and beyond Hospice: Continued growth at high single / low double digit pace (Admissions +8%, ADC +12%) for 4Q’17 Home Health: BD FTE ramp continuing to progress and impacting growth. Same store episodic admissions +3%, non-episodic admissions
Slide 5: Highlights and Summary Financial Results (Adjusted): 4Q 2017
Highlights and Summary Financial Results (Adjusted): 4Q 2017(1) Same store Home Health Episodic admissions up (+3%) excluding Florida closures. Hospice (+8% same store admissions) and Personal Care (+43% billable hours) continue their strong growth Amedisys Consolidated Revenue Growth: +11% EBITDA:
Slide 6: Our revenue sources
Our revenue sources Medicare FFS: Paid episodically over a 60 day episode Private Episodic: MA and Commercial plans who pay us over a 60 day episode. Generally at rates ~90% – 100% of Medicare Per Visit: Managed care, Medicaid and private payors reimbursing us per visit provided Per Day Reimbursemen
Slide 7: Home Health and Hospice Segment (Adjusted) – 4Q 2017
Home Health and Hospice Segment (Adjusted) – 4Q 2017(1) Overall same store episodic admissions ex. FL closures +3% Total same store episodic volume growth +6% (admissions plus recertifications) [ex. Florida closures] Y/Y CPV decrease of (0.1%) in 4Q Home Health Highlights Same store average daily ce
Slide 8: General & Administrative Expenses – Adjusted
General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue decreased 180 basis points Home Health segment G&A: 80 bps y/y decrease as % of revenue Hospice segment G&A: 20 bps decrease y/y as % of revenue Personal Care segment G&A: 20 bps increase y/
Slide 9: Status of Key Initiatives
Status Category Update Ongoing Initiative Quality ratings (Stars & VBP) Amedisys improves quality of patient care star sore to 4.30 in the April 2018 HHC preview with 89% of providers at 4+ Stars; focusing on readmission reduction; Hospice quality metrics initially released Clinical Initiatives & Re
Slide 10: Star scores continue to trend upwards: Among industry leaders
Star scores continue to trend upwards: Among industry leaders Note: Top Competitor Avg weighted by CCN count and include LHC, Kindred, AFAM, HLS and BKD Metric OCT 17 Release JAN 18 Release APR 18 PREVIEW Quality of Patient Care 4.13 4.22 4.30 Entities at 4+ Stars 81% 88% 89% Metric JUL 17 Release O
Slide 11: Hospice Quality
Hospice Quality * Analyses examined outcomes for patients with a primary diagnosis related to heart failure, and found that patients in the Heart Failure (HF) program were significantly less likely to be hospitalized within 30 days (p < 0.0001) and within 60 days (p < 0.0001) than those who were not
Slide 12: Business development FTE ramp
Dotted lines represent projections Adjusting for Florida closures (20 BD FTE’s) we achieved our 4Q’17 BD FTE’s target On Target to Reach 775 BD FTEs by End of 4Q’17 Vacancy Rate goal of 6% by YE 2017 achieved and surpassed BD recruiting SWAT team responsible for the significant ramp in BD FTEs Decli
Slide 13: $46 Million in Targeted Savings by Q4 2017
In early 2015, we discussed a plan to deliver $46M in annualized run rate savings by the end of this year and have achieved much of this to date, which has driven improved margins $46 million in Targeted Savings by Q4 2017
Slide 14: Home Health cost per visit components
Components 4Q’16 3Q’17 4Q’17 YoY Variance Detail Mitigation Plan Salaries $62.94 $61.65 $61.80 ($1.14) YoY decrease driven by increased productivity. Sequential increase due to planned salary increases Staffing mix optimization, productivity and scheduling improvement initiatives in place helped us
Slide 15: Why Invest in Hospice
Why Invest in Hospice Hospice segment primed for further investment Patient Volumes 6-Year CAGR of 4.0% Medicare Spending 6-Year CAGR of 5.7% Medicare cost per day Most Cost Efficient Setting of Care Percentage of Hospice Providers (4,199 total providers) Aggregate Medicare Margins N/A 1 Our organiz
Slide 16: Driving Top Line Growth: Hospice
Driving Top Line Growth: Hospice Amedisys Hospice continues its amazing performance Hospice Admits, ADC and Revenue
Slide 17: Driving Top Line Growth: Home Health
Driving Top Line Growth: Home Health Total episodic volume growth continues to improve reaching 7.0% in 4Q 234 Opportunities Prospected 45 Opportunities Under Review 13 Active Processes Home Health Total Episodic Volume (ex. Florida closures)
Slide 18: Driving Top Line Growth: Personal Care
Driving Top Line Growth: Personal Care Our Personal Care team has grown via acquisition and are now expert integrators 234 Opportunities Prospected 45 Opportunities Under Review 13 Active Processes Personal Care Total Hours / Quarter* * Includes closed acquisitions (1) East TN Personal Care Services
Slide 19: Debt and Liquidity Metrics
Debt and Liquidity Metrics Our debt levels remain very low (0.0x net leverage ratio) providing us ample flexibility and available liquidity for strategic initiatives and inorganic growth opportunities Net debt defined as total debt outstanding ($91M) less cash balance ($86M). Leverage ratio (net) is
Slide 20: Cash Flow Statement Highlights
Cash Flow Statement Highlights (1) $29.7M in free cash flow for the quarter and $95.1 million for the year, with $33.7M in capital deployed to M&A opportunities Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.
Slide 21: Income Statement Adjustments
Income Statement Adjustments (1) Amount of non-GAAP adjustments, excluding Florida ZPIC audit, legal settlements and deferred tax adjustment, have substantially decreased. Trend to continue throughout 2018. The financial results for the three-month periods ended March 31, 2017, June 30, 2017, Septem
Slide 22: 2018 Guidance Discussion
2018 Guidance Discussion
Slide 23: Amedisys 2018 Preliminary Guidance
Amedisys 2018 Preliminary Guidance Targeting 7% growth in revenue and 13% growth in EBITDA; EPS includes impact of tax reform. 2017 2018 Revenue Adjusted EBITDA $142.2M $1.54B $1.52B* Adjusted Earnings per Share $2.21 $158M – $163M $1.60B - $1.64B $2.97 – $3.08 *See slide 26 for estimated impact to
Slide 24: Amedisys 2018 Preliminary Guidance Considerations
Amedisys 2018 Preliminary Guidance Considerations Amedisys Consolidated Tax rate ~26 - 27% (includes impact from Tax Cuts and Jobs Act) Cash tax rate ~ 5% Diluted share count ~34.85 million shares Excludes potential acquisitions and related integration costs Capital Expenditures ~$7-$9 million Benef
Slide 25: Reimbursement Outlook
Reimbursement Outlook 2018 Reimbursement Impact for Home Health and Hospice Home Health Hospice 2018 Market Basket Update 1.0% Nominal Case Mix Adjustment -0.90 Estimated Industry Impact +0.1% Estimated AMED-Specific Impact -0.7% 2018 Market Basket Update 1.0% Productivity / Other Adjustment __ Esti
Slide 26: Estimated Impact of Adoption of New Revenue Recognition Accounting Standard
Estimated Impact of Adoption of New Revenue Recognition Accounting Standard Amedisys will retrospectively adopt Accounting Standards Updates (“ASU”) 2014-09 & 2015-14, Revenue from Contracts with Customers (Topic 606), effective January 1, 2018. Amounts previously recognized as “Provision for Doubtf
Slide 27: EBITDA Seasonality
EBITDA Seasonality Q1 Q2 Q3 Q4 Drivers of Seasonality Weather disruption Lower RPE (LUPA) Payroll tax reset Short Month (Feb.) Lower Hospice ADC & Higher Salary Cost per Day Highest Completed Episodes Stronger RPE Incremental holiday vs. 1H High PTO Lower Volumes Health Insurance Increases Raises In